TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28770947

Group type: EXPERIMENTAL
Intervention: Anti-epileptic therapy with vitamin B12 (mecobalamin)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Anti-epileptic therapy with compound vitamin B tablets
Number of subjects: 90

Group type: COMPARATOR
Intervention: Single-agent or combination anti-epileptic therapy with oxcarbazepine and sodium valproate
Number of subjects: 90
Study: 25837751

Group type: EXPERIMENTAL
Intervention: PM/Ca (sodium picosulfate, magnesium oxide, and citric acid)
Number of subjects: 209

Group type: COMPARATOR
Intervention: PEG (polyethylene glycol)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: PM/Ca
Number of subjects: 209

Group type: COMPARATOR
Intervention: PEG
Number of subjects: 209
Study: 23956857

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg of lignocaine hydrochloride
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg of dexamethasone
Number of subjects: 114

Group type: COMPARATOR
Intervention: 5 mL of preservative-free saline
Number of subjects: 114
Study: 20689465

Group type: EXPERIMENTAL
Intervention: Lasofoxifene 0.25 mg/day
Number of subjects: 8556

Group type: EXPERIMENTAL
Intervention: Lasofoxifene 0.5 mg/day
Number of subjects: 8556

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8556
Study: 19009227

Group type: EXPERIMENTAL
Intervention: Calcium supplemented bread (1.0 g/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Calcium supplementation
Number of subjects: 31
Study: 17530493

Group type: EXPERIMENTAL
Intervention: Stop & Think! program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study: 15014300

Group type: EXPERIMENTAL
Intervention: Concomitant administration of Comvax, M‐M‐RII and Varivax
Number of subjects: 822

Group type: COMPARATOR
Intervention: Nonconcomitant administration of Comvax followed by M‐M‐RII and Varivax 6 weeks later
Number of subjects: 822
Study: 11605094

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.25 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alprazolam 1.0 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9850204

Group type: EXPERIMENTAL
Intervention: Sertraline (50, 100 or 200 mg)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 178
Study: 7866474

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 1026

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1026
Study: 2479187

Group type: EXPERIMENTAL
Intervention: Recombinant human interferon-alpha (0.5 x 10^6 U)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Recombinant human interferon-alpha (1.5 x 10^6 U)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Recombinant human interferon-gamma (0.25 x 10^6 IU)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Recombinant human interferon-gamma (1.0 x 10^6 IU)
Number of subjects: 72
Study: 775265

Group type: EXPERIMENTAL
Intervention: AN 448 Sandoz (mazindol)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30649711

Group type: EXPERIMENTAL
Intervention: Riomet® ER Strawberry
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Riomet® ER Grape
Number of subjects: 56

Group type: COMPARATOR
Intervention: Riomet® Cherry
Number of subjects: 56

Group type: COMPARATOR
Intervention: Metformin IR crushed tablets
Number of subjects: 56
Study: 28762527

Group type: EXPERIMENTAL
Intervention: Eliglustat (9 months initial treatment, followed by 9 months in extension)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Eliglustat (during 9-month open-label period for placebo group)
Number of subjects: 40
Study: 25209598

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14264

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14264

Group type: COMPARATOR
Intervention: Rivaroxaban vs. Warfarin
Number of subjects: 14264
Study: 23735473

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg BID
Number of subjects: 56

Group type: COMPARATOR
Intervention: Prasugrel 10 mg OD
Number of subjects: 56
Study: 21219403

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid (amoxiclav)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 18046564

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasonography (USG)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Doppler ultrasonography (USG)
Number of subjects: 120
Study: 16798773

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% 0.75 ml kg(‐1) with tramadol 2 mg kg(‐1) (Group BT2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: bupivacaine 0.25% 0.75 ml kg(‐1) (Group B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% 0.75 ml kg(‐1) with tramadol 1 mg kg(‐1) (Group BT1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% 0.75 ml kg(‐1) with tramadol 1.5 mg kg(‐1) (Group BT1.5)
Number of subjects: 80
Study: 12780360

Group type: EXPERIMENTAL
Intervention: Regular scratchcard gambling
Number of subjects: 12222

Group type: EXPERIMENTAL
Intervention: Potential problematic scratchcard gambling
Number of subjects: 12222

Group type: EXPERIMENTAL
Intervention: Pathological scratchcard gambling (PSG)
Number of subjects: 12222

Group type: EXPERIMENTAL
Intervention: Unique PSG
Number of subjects: 12222

Group type: EXPERIMENTAL
Intervention: Combined PSG
Number of subjects: 12222

Group type: EXPERIMENTAL
Intervention: Demographic characteristics of combined PSG
Number of subjects: 12222

Group type: EXPERIMENTAL
Intervention: Demographic characteristics of unique PSG
Number of subjects: 12222
Study: 11079528

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg x kg(‐1) body mass)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Caffeine (9 mg x kg(‐1) body mass)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9354537

Group type: EXPERIMENTAL
Intervention: Low-dose sotalol (80 mg twice daily)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Low-dose sotalol
Number of subjects: 255
Study: 8222651

Group type: EXPERIMENTAL
Intervention: Prolonged regimen (9 weeks on, 1 week off)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Standard regimen (3 weeks on, 1 week off)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Prolonged regimen
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Women already using OC
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 294
Study: 3759774

Group type: COMPARATOR
Intervention: Unloaded exercise tests (first and last test)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Resistive loading (33, 57, and 73 cm H2O X l‐1 X s) during exercise tests
Number of subjects: 6
Study: 30922544

Group type: EXPERIMENTAL
Intervention: Mental skills training
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no mental skills training)
Number of subjects: 38
Study: 30111163

Group type: EXPERIMENTAL
Intervention: Self‐ and Family Management Intervention (SAFMI)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control
Number of subjects: 41
Study: 27048282

Group type: EXPERIMENTAL
Intervention: Child-initiated intervention program
Number of subjects: 308

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 308
Study: 25002239

Group type: EXPERIMENTAL
Intervention: Mobile phone short message reminder
Number of subjects: 703

Group type: COMPARATOR
Intervention: Usual appointment track (Control)
Number of subjects: 703
Study: 23461152

Group type: EXPERIMENTAL
Intervention: Blue light filtering lens
Number of subjects: 99

Group type: COMPARATOR
Intervention: Lens without blue light filter
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Own transparent lens
Number of subjects: 99
Study: 20226143

Group type: EXPERIMENTAL
Intervention: Traditional Chinese herbal medicine (TCHM) plus chemotherapy
Number of subjects: 220

Group type: COMPARATOR
Intervention: Chemotherapy only (non-TCHM group)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: TCHM treatment in late stage patients
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: TCHM treatment with radical resection and chemotherapy
Number of subjects: 220

Group type: COMPARATOR
Intervention: Chemotherapy only with radical resection and chemotherapy (non-TCHM group)
Number of subjects: 220
Study: 17715033

Group type: EXPERIMENTAL
Intervention: Periodic tamoxifen treatment
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Consecutive tamoxifen treatment
Number of subjects: 109
Study: 15209316

Group type: EXPERIMENTAL
Intervention: Self-selected motivational music
Number of subjects: 27

Group type: COMPARATOR
Intervention: White noise
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Prior Exposure (music or white noise before task)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Half Exposure (music or white noise during task for half the duration)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Full Exposure (music or white noise during entire task)
Number of subjects: 27
Study: 11519931

Group type: EXPERIMENTAL
Intervention: Dispositional self-control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-the-moment self-regulatory strength
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-control (Study 3)
Number of subjects: 0
Study: 9575997

Group type: EXPERIMENTAL
Intervention: Reusable hook cautery instruments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Limited-reuse hook cautery instruments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Limited-reuse curved scissors
Number of subjects: 0
Study: 8157768

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg daily)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 3046405

Group type: EXPERIMENTAL
Intervention: Extracts composed of any combination of alder, birch and hazel pollen (Group 1 (ABC))
Number of subjects: 54

Group type: COMPARATOR
Intervention: Birch pollen extracts (Group 2 (B))
Number of subjects: 54
Study: 31809359

Group type: EXPERIMENTAL
Intervention: Personalized recommendation
Number of subjects: 236

Group type: COMPARATOR
Intervention: Standard HIV testing information
Number of subjects: 236
Study: 30222831

Group type: EXPERIMENTAL
Intervention: Tourniquet use in Case 1 (no bleeding)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Tourniquet use in Case 2 (limb-wound bleeding)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Tourniquet use in Case 3 (child with limb-wound bleeding)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Tourniquet use in Case 4 (limb-wound bleeding under gunfire)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Tourniquet use in Case 5 (two tourniquets side by side under gunfire)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Mechanical performance across all cases
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Block 1 (first block of tests)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Block 2 (second block of tests)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Block 3 (third block of tests)
Number of subjects: 4
Study: 27760790

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 0
Study: 26591200

Group type: EXPERIMENTAL
Intervention: b2-adrenomimetic (fenoterol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: anticholinergic (ipratropium bromide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: combined preparation (fenoterol/ipratropium bromide)
Number of subjects: 0
Study: 23747795

Group type: EXPERIMENTAL
Intervention: Transarterial hepatic (TAH) delivery of indocyanine green (ICG)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intravenous (IV) delivery of indocyanine green (ICG)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Comparison of TAH vs IV delivery of ICG
Number of subjects: 9
Study: 21627558

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once a week and calcium with vitamin D
Number of subjects: 80

Group type: COMPARATOR
Intervention: Calcium with vitamin D
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once a week
Number of subjects: 80
Study: 18978619

Group type: EXPERIMENTAL
Intervention: Morning rowing performance (M-type subjects)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Evening rowing performance (E-type and N-type subjects)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standing broad jump performance
Number of subjects: 16
Study: 16552372

Group type: EXPERIMENTAL
Intervention: Single mesh technique
Number of subjects: 65

Group type: COMPARATOR
Intervention: Double mesh technique
Number of subjects: 65
Study: 12679710

Group type: EXPERIMENTAL
Intervention: Nutritional status improvement and treatment of parasitic infections
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Baseline MUAC, education level, serum retinol and selenium concentrations, clinical stage of HIV disease, malaria infection
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Low baseline CD4 T-cell counts
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Weight gain measurement
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Change in mid-upper arm circumference (MUAC)
Number of subjects: 957
Study: 10999648

Group type: EXPERIMENTAL
Intervention: Colestipol/niacin
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 2
Study: 9457388

Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m2, day 0) plus continuous intravenous infusion rIL-2 (18 MIU/m2/day, days 3-6 and days 17-21) and subcutaneous rIFN-alpha (9 MIU three times per week)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Cisplatin plus rIL-2 and rIFN-alpha
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Cisplatin plus rIL-2 and rIFN-alpha with tamoxifen (160 mg/day)
Number of subjects: 129
Study: 8440759

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (20, 50, 80 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dexamethasone (20, 50, 80 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (20, 50, 80 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 4063010

Group type: EXPERIMENTAL
Intervention: Community nursing homes (CNHs)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Veterans Administration nursing care units
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Continued care on the same ward
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Transfer to another psychiatric ward
Number of subjects: 403

Group type: COMPARATOR
Intervention: Drug use
Number of subjects: 403

Group type: COMPARATOR
Intervention: Cost
Number of subjects: 403
Study: 31296273

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma applied to the tonsillar bed post-operatively
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control side (no intervention)
Number of subjects: 0
Study: 29421003

Group type: EXPERIMENTAL
Intervention: Positioning the instrumented right arm far from the body
Number of subjects: 14

Group type: COMPARATOR
Intervention: Positioning the instrumented right arm close to the right leg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Use of a smaller full glass shield
Number of subjects: 14

Group type: COMPARATOR
Intervention: Use of a larger composite shield
Number of subjects: 14
Study: 27866182

Group type: EXPERIMENTAL
Intervention: Homeopathic treatment (9 drugs including Pulsatilla nigricans, Sepia succus, Lycopodium clavatum, sulphur, Lachesis trigonocephalus, Nux vomica, Calcarea carbonica, phosphorus, Conium maculatum) administered as 6 drops orally 2 times per day for 4 consecutive days each week, with a 3-day interval between doses.
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group received placebo drug and diet orientation.
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 134
Study: 1444292

Group type: EXPERIMENTAL
Intervention: Cefotaxime, 2 g intravenously at 6‐h intervals during surgery and then at 8‐h intervals thereafter for 48 h
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ampicillin, 2 g intravenously at the same dose and schedule as cefotaxime
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Systemic antibiotics plus a 3‐week regimen of oral nonabsorbable antibiotics (gentamicin, polymyxin E, and nystatin)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Systemic antibiotics alone
Number of subjects: 18
Study: 22902138

Group type: EXPERIMENTAL
Intervention: Bilateral grade III mobilization of the talocrural joint
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 32
Study: 20412151

Group type: EXPERIMENTAL
Intervention: Airway Scope
Number of subjects: 100

Group type: COMPARATOR
Intervention: McCoy laryngoscope
Number of subjects: 100
Study: 18708988

Group type: EXPERIMENTAL
Intervention: Intraarticular lumbar facet joint injections with lidocaine and triamcinolone
Number of subjects: 46

Group type: COMPARATOR
Intervention: Medial branch nerve blocks with lidocaine and triamcinolone
Number of subjects: 46
Study: 15877992

Group type: EXPERIMENTAL
Intervention: Resistance exercise (6 months)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 15
Study: 12209099

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg/d for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 30
Study: 10604096

Group type: EXPERIMENTAL
Intervention: Acute pancreatitis
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Chronic pancreatitis
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pancreatic carcinoma
Number of subjects: 72

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 72
Study: 8961368

Group type: COMPARATOR
Intervention: Whole Brain Irradiation (WBI)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Focused Irradiation (FI)
Number of subjects: 30
Study: 1763561

Group type: EXPERIMENTAL
Intervention: Low-dose antacid (AA) therapy (225 meq total neutralizing capacity per day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low-dose antacid (AA) therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Misoprostol (MS) therapy (400 micrograms bid)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Misoprostol (MS) therapy
Number of subjects: 100
Study: 6433840

Group type: EXPERIMENTAL
Intervention: Low dose urokinase (UKl): 2000 IU/kg/hour associated with heparin
Number of subjects: 129

Group type: COMPARATOR
Intervention: High dose urokinase (UKh): 4400 IU/kg/hour for 12 hours followed by heparin
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Low dose urokinase (UKl)
Number of subjects: 129

Group type: COMPARATOR
Intervention: High dose urokinase (UKh)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 129
Study: 31567622

Group type: EXPERIMENTAL
Intervention: Initial diagnosis of glaucoma based on strict criteria from 2 visual field tests and optic disc findings if borderline
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Initial diagnosis of glaucoma
Number of subjects: 255
Study: 29630134

Group type: EXPERIMENTAL
Intervention: Voriconazole sequential therapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 110
Study: 27292585

Group type: EXPERIMENTAL
Intervention: Testosterone therapy every 2 weeks for 15 weeks
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo treatment every 2 weeks for 15 weeks
Number of subjects: 94
Study: 24256699

Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg/day)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg/day)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Combination of fluvastatin (40 mg/day) and diltiazem (90 mg/day)
Number of subjects: 68
Study: 22479786

Group type: EXPERIMENTAL
Intervention: HM-302 mouth rinse
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cetylpyridinium chloride (CPC) rinse
Number of subjects: 62

Group type: COMPARATOR
Intervention: Essential oils (EO) rinse
Number of subjects: 62

Group type: COMPARATOR
Intervention: Water-only preparation
Number of subjects: 62
Study: 21427997

Group type: EXPERIMENTAL
Intervention: indigal plus (2 capsules twice a day for 3 months) and sparfloxacin (200 mg twice a day for 1 month)
Number of subjects: 30

Group type: COMPARATOR
Intervention: sparfloxacin alone (200 mg twice a day for 1 month)
Number of subjects: 30
Study: 18042106

Group type: EXPERIMENTAL
Intervention: Natalizumab 300 mg every 4 weeks for 48 weeks (N=168)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo every 4 weeks for 48 weeks (N=171)
Number of subjects: 339
Study: 17885311

Group type: EXPERIMENTAL
Intervention: Object present (holding a glass)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Object absent (no object)
Number of subjects: 66
Study: 15574070

Group type: EXPERIMENTAL
Intervention: KLIP program (knee ligament injury prevention program), low-intensity plyometric exercises, 9 weeks duration, twice a week
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study: 10881808

Group type: EXPERIMENTAL
Intervention: FloSeal Matrix
Number of subjects: 93

Group type: COMPARATOR
Intervention: Gelfoam‐Thrombin (control group)
Number of subjects: 93
Study: 9178671

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg twice daily
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 1489073

Group type: EXPERIMENTAL
Intervention: Magnesium aspartate infusion (0.8 mEq/kg per h for 15 min, then reduced to 0.2 mEq/kg per h until aortic cannulation)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no magnesium infusion)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Magnesium aspartate infusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 4045758

Group type: EXPERIMENTAL
Intervention: Direct informational feedback using videotape recordings
Number of subjects: 8
Study: 30704873

Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg/day)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257